Innovative tuberculosis trial starts in Sindh province, Pakistan | MSF - Médecins Sans Frontières (MSF) International

-

Karachi/Paris – Médecins Sans Frontières and Interactive Research and Development (IRD) have announced the start of a clinical trial in Pakistan that aims to find better, shorter treatments against multidrug-resistant forms of tuberculosis (MDR-TB).

The endTB trial is a phase III randomized controlled trial comparing five new treatment regimens against MDR-TB which contain two of the three new tuberculosis (TB) drugs developed in recent years, bedaquiline and delamanid, in combination with other existing oral TB drugs.

A related, parallel trial, called endTB-Q, will evaluate a sixth treatment combination and two different treatment durations, to be used against forms of MDR-TB which are also resistant to fluoroquinolones, a group of antibiotics used as so-called ‘second-line’ drugs in the treatment of TB.

Together, the two trials will identify the most effective and less toxic all-oral, shorter (between six and nine months) treatment regimens against the deadliest forms of TB.

Between its start in March 2017 and the end of September 2019, 344 patients have already been enrolled in the endTB trial across five countries, namely Georgia, Kazakhstan, Lesotho, Peru and South Africa.

Tuberculosis (TB) is the deadliest infectious disease worldwide, with an estimated 1.5 million deaths each year, according to the World Health Organization.

MDR-TB represents a particularly deadly form of the disease. Its treatment requires combining at least four effective drugs for up to 24 months – the length and toxicity of which are often hard to manage. In 2018, only one out of three patients was put under an effective treatment, and among those who were, only half were cured.<a href="https://ift.tt/2N3fNO9> WHO Tuberculosis Fact Sheet 2018</a>



https://ift.tt/2NxkEX9

Comments

Post a Comment

Popular posts from this blog

Manual on meat inspection for developing countries

-
Image
sinusitis treatment :: Article Creator My 'sinus Infection' Turned Out To Be A One In A Million Nasal Cancer At Just 28 - And Doctors Had To Cut My Eye Out To Save Me By Emily Joshu Health Reporter For Dailymail.Com Published: 06:33 EDT, 20 April 2024Updated: 06:35 EDT, 20 April 2024 A 28 year-old California woman has described the shock of being diagnosed with a deadly sinus cancer that affects fewer than one in a million people - and led to the removal of her right eye. The 'golf ball-sized tumor', which had spread throughout her face, was first mistaken for a sinus infection by the woman's doctors.  Annika, who posts about her condition on TikTok, woke up one morning in 2023 and noticed that the inner corner of her right eye was sore.  While she at first thought nothing of it, by the time the evening rolled around, 'my face started to really, really hurt on the right side,' she said in a video.  The next day, her
Read more

Rash behind ear: Causes, other symptoms, and treatment - Medical News Today

-
Image
A rash behind the ear may occur due to a variety of different medical conditions. Certain viral infections and autoimmune diseases may cause a rash behind the ear in both children and adults. While some causes, such as contact dermatitis, are not concerning, other causes, including rubella, may be more serious. In this article, we look at some of the causes of a rash behind the ear, as well as the other symptoms that they may produce and how to treat them. Contact dermatitis is an allergic reaction to a particular substance. If an allergy-inducing substance comes into contact with the skin behind the ear, a rash can form. Allergens that may cause contact dermatitis behind the ears include: shampoos soaps other hair care products For example, hair dye products contain an ingredient called paraphenylenediamine (PPD), which is a common contact allergen. Symptoms Contact dermatitis causes itchiness, dryness, and flaking of the skin that came into contact with the allergen. Diagnosis A doc
Read more

Having This One Particular Blood Type Can Help Protect You From Severe Malaria - ScienceAlert

-
Image
Nearly  half the world's population is at risk of malaria, one of the most deadly diseases known to humankind. Each year it claims  over 400,000 lives, most of whom are children younger than age five. While it's possible to vaccinate against malaria, virtually all of these cases are in the African region, where protection is often nothing more than a roll of the dice. Now, a recent  analysis  of 23 papers suggests those with blood type O have the genetic odds stacked in their favour. In sub-Saharan Africa, where severe malaria - caused by the  Plasmodium falciparum  parasite  - is endemic, there are far more individuals with blood type O than anywhere in Europe or the US. In Nigeria alone, where 97 percent of the country is at risk of malaria, more than half the population belongs to this blood group. In Ethiopia and many others, the numbers are similar. Rather than a coincidence, co-author and epidemiologist Abraham Degarege Mengist from Robert Stempel College of Publi
Read more